Skip to main content
. Author manuscript; available in PMC: 2017 Sep 14.
Published in final edited form as: Anal Chem. 2017 Apr 17;89(9):4838–4846. doi: 10.1021/acs.analchem.6b04436

Figure 4. Remicade and Remsima glycosylation heterogeneity and FcγR-IIIa binding.

Figure 4

A, Quantification of N-glycans following LC/MS/MS analysis of RC B, total mannose terminated forms C, total afucosylated forms. D, Average KD of RC and RS receptor binding to FcγIIIa as measured by biolayer interferometry (n = 4 lots, mean ± SEM; * denotes significance at p<0.05).